New Issue: Genitope raises $54.4 million in follow-on of 6.4 million shares at $8.50 vs. $8.93 close

By Ronda Fears

Memphis, Feb. 7 - Genitope Corp. sold an upsized $54.4 million follow-on offering of 6.4 million shares, boosted from 4.5 million shares, at $8.50 - discounted from Monday's close of $8.93.

WR Hambrecht & Co. was bookrunner, and RBC Capital was joint lead manager.

Redwood City, Calif.-based Genitope is focused on cancer treatments. Its lead product candidate, MyVax Personalized Immunotherapy, is a patient-specific active immunotherapy based on the unique genetic makeup of a patient's tumor and is designed to activate the patient's immune system to identify and attack cancer cells.

Issuer:	Genitope Corp.
Issue:	Follow-on stock offering
Proceeds:	$54.4 million
Shares:	6.4 million shares, up from 4.5 million
Greenshoe:	960,000 shares, up from 675,000
Price:	$8.50 per share
Bookrunner:	WR Hambrecht & Co.
Joint lead manager:	RBC Capital
Co-managers:	Brean Murray, Carret & Co. LLC and Punk, Ziegel & Co.
Pricing date:	Feb. 6
Settlement date:	Feb. 10
Stock symbol:	Nasdaq: GTOP
Stock price:	$8.93 at close Feb. 6

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.